Market Cap 20.73B
Revenue (ttm) 29.05M
Net Income (ttm) -171.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -592.01%
Debt to Equity Ratio 0.00
Volume 8,437,000
Avg Vol 5,506,710
Day's Range N/A - N/A
Shares Out 715.70M
Stochastic %K 82%
Beta 1.14
Analysts Strong Sell
Price Target $35.67

Company Profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythemat...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7400 3347
Website: roivant.com
Address:
50 Broadway, 7th Floor, London, United Kingdom
sheepmanct
sheepmanct May. 12 at 5:31 PM
$ROIV https://investor.roivant.com/node/13186/html
0 · Reply
NakdEnergy
NakdEnergy May. 12 at 12:14 PM
$ABUS I really believe this was and is an orchestrated screw job of the retail shareholders. Ousting the original management was the bull horn we should have listened to. $ROIV has been pulling the strings the whole time and ‘will not’ allow any settlement that would ruin their ‘Big Pharma’ relationships. This is Wall Street crookedness at its best because they did it in a way ‘all out front’ that no body could successfully take them to court. We wasted years of putting good capital to work and when we finally force a settlement, “The Stock Goes Down” You can’t make this crap up! Hope all those retail investors do well in their other investments! We deserved better IMO!
2 · Reply
sheepmanct
sheepmanct May. 11 at 9:19 PM
$ROIV earnings will be on 5/20. Call will be at 800am ET. Press release is usually released at 700am. IMVT (Immunovant) releasing same day and time. Maybe ABUS on 5/20? https://investor.roivant.com/news-releases/news-release-details/roivant-report-financial-results-fourth-quarter-and-fiscal-2/
0 · Reply
mj6534
mj6534 May. 9 at 2:05 AM
$ABUS Sick and tired of $ROIV using us as a shell company. I can’t believe we’ve been getting bs’ed for nearly 6 years now. Unbelievable
2 · Reply
bbbloo
bbbloo May. 6 at 9:40 PM
$ROIV this just keeps creeping up and up little by little. it doesn’t seem to catch attention but just keeps going up slowly. it is actually doing really well!
0 · Reply
CapitalMonk
CapitalMonk May. 6 at 7:44 PM
$ROIV Price: $28.67 (+1.25%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±2.11% RSI: 46.3 | Momentum: Moderate Volume: -52.5% vs avg Volatility: 1.91% Support: $27.06 | Resistance: $30.18 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
Jblack500
Jblack500 May. 5 at 7:32 PM
@MaverikIT @No_Face_character @cynicaloptimist @IsabellaDC @BustaCapital @WAJeff Michelle Ross, stud biotech investor on CNBC right now giving the pump to $RVMD and $ROIV and she is still in $ABVX. i was in roivant for nice gain in the past. She is one of the best to get ideas from
2 · Reply
StockSqueeze_
StockSqueeze_ Apr. 28 at 10:00 PM
Live Account Update Red day today. Down 0.79%. I have two option calls I chased which are both red. Still holding $VOO and $GOOG Picked up $ET and $ROIV today. Back at it again tomorrow. How did you do today? 🤔
0 · Reply
dick_dasterdly
dick_dasterdly Apr. 21 at 10:29 PM
$ROIV Bought this @ $11.13 back on July 18th , 2024. Slowly but surely here folks. Loonnggg play for me. Rich pipeline. And consolidating each and every day..
0 · Reply
NettyLite
NettyLite Apr. 21 at 7:28 PM
$ROIV I thought about also buying Abus but with the slightest bit of research I realized that would be dumb. Abus is roiv's bitch. Y'all didn't do your research now go home and get your shine box
0 · Reply
Latest News on ROIV
Roivant Sciences assumed with an Overweight at Piper Sandler

2026-04-16T14:07:55.000Z - 26 days ago

Roivant Sciences assumed with an Overweight at Piper Sandler


Roivant Sciences Transcript: Study result

Apr 2, 2026, 8:00 AM EDT - 5 weeks ago

Roivant Sciences Transcript: Study result


Roivant Sciences initiated with an Outperform at Bernstein

2026-03-19T20:22:56.000Z - 7 weeks ago

Roivant Sciences initiated with an Outperform at Bernstein


Roivant Sciences Transcript: Status update

Mar 3, 2026, 4:45 PM EST - 2 months ago

Roivant Sciences Transcript: Status update


Roivant Sciences price target raised to $35 from $26 at Citi

2026-02-10T11:36:43.000Z - 3 months ago

Roivant Sciences price target raised to $35 from $26 at Citi


Roivant Sciences price target raised to $26 from $22 at BofA

2026-02-09T13:40:17.000Z - 3 months ago

Roivant Sciences price target raised to $26 from $22 at BofA


Roivant Sciences Earnings Call Transcript: Q3 2026

Feb 6, 2026, 8:00 AM EST - 3 months ago

Roivant Sciences Earnings Call Transcript: Q3 2026


Roivant Sciences Transcript: Investor Day 2025

Dec 11, 2025, 8:00 AM EST - 5 months ago

Roivant Sciences Transcript: Investor Day 2025


Roivant Sciences Earnings Call Transcript: Q2 2026

Nov 10, 2025, 8:00 AM EST - 6 months ago

Roivant Sciences Earnings Call Transcript: Q2 2026


Roivant Sciences Transcript: Study Result

Sep 17, 2025, 8:00 AM EDT - 8 months ago

Roivant Sciences Transcript: Study Result


Roivant Sciences Transcript: Study Update

Sep 3, 2025, 4:30 PM EDT - 8 months ago

Roivant Sciences Transcript: Study Update


Roivant Sciences Earnings Call Transcript: Q1 2026

Aug 11, 2025, 8:00 AM EDT - 9 months ago

Roivant Sciences Earnings Call Transcript: Q1 2026


Roivant Sciences Transcript: Status Update

Jun 17, 2025, 1:00 PM EDT - 11 months ago

Roivant Sciences Transcript: Status Update


Roivant Sciences Earnings Call Transcript: Q4 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Earnings Call Transcript: Q4 2025


Roivant Sciences Transcript: Status Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Transcript: Status Update


Roivant Sciences Earnings Call Transcript: Q3 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Roivant Sciences Earnings Call Transcript: Q3 2025


Roivant's lung disease drug fails mid-stage trial

Dec 3, 2024, 7:19 AM EST - 1 year ago

Roivant's lung disease drug fails mid-stage trial


Roivant Sciences Earnings Call Transcript: Q2 2025

Nov 12, 2024, 8:00 AM EST - 1 year ago

Roivant Sciences Earnings Call Transcript: Q2 2025


Roivant Flips a Skin Drug to Organon

Sep 18, 2024, 10:59 AM EDT - 1 year ago

Roivant Flips a Skin Drug to Organon

OGN


Roivant Sciences Transcript: Study Update

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Roivant Sciences Transcript: Study Update


Roivant Sciences Earnings Call Transcript: Q1 2025

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Roivant Sciences Earnings Call Transcript: Q1 2025


Roivant Sciences Earnings Call Transcript: Q4 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Earnings Call Transcript: Q4 2024


Roivant Sciences Transcript: Status Update

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Transcript: Status Update


Roivant's anti-inflammatory drug succeeds in mid-stage study

Apr 2, 2024, 7:28 AM EDT - 2 years ago

Roivant's anti-inflammatory drug succeeds in mid-stage study


Roivant Sciences Earnings Call Transcript: Q3 2024

Feb 13, 2024, 8:00 AM EST - 2 years ago

Roivant Sciences Earnings Call Transcript: Q3 2024


sheepmanct
sheepmanct May. 12 at 5:31 PM
$ROIV https://investor.roivant.com/node/13186/html
0 · Reply
NakdEnergy
NakdEnergy May. 12 at 12:14 PM
$ABUS I really believe this was and is an orchestrated screw job of the retail shareholders. Ousting the original management was the bull horn we should have listened to. $ROIV has been pulling the strings the whole time and ‘will not’ allow any settlement that would ruin their ‘Big Pharma’ relationships. This is Wall Street crookedness at its best because they did it in a way ‘all out front’ that no body could successfully take them to court. We wasted years of putting good capital to work and when we finally force a settlement, “The Stock Goes Down” You can’t make this crap up! Hope all those retail investors do well in their other investments! We deserved better IMO!
2 · Reply
sheepmanct
sheepmanct May. 11 at 9:19 PM
$ROIV earnings will be on 5/20. Call will be at 800am ET. Press release is usually released at 700am. IMVT (Immunovant) releasing same day and time. Maybe ABUS on 5/20? https://investor.roivant.com/news-releases/news-release-details/roivant-report-financial-results-fourth-quarter-and-fiscal-2/
0 · Reply
mj6534
mj6534 May. 9 at 2:05 AM
$ABUS Sick and tired of $ROIV using us as a shell company. I can’t believe we’ve been getting bs’ed for nearly 6 years now. Unbelievable
2 · Reply
bbbloo
bbbloo May. 6 at 9:40 PM
$ROIV this just keeps creeping up and up little by little. it doesn’t seem to catch attention but just keeps going up slowly. it is actually doing really well!
0 · Reply
CapitalMonk
CapitalMonk May. 6 at 7:44 PM
$ROIV Price: $28.67 (+1.25%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±2.11% RSI: 46.3 | Momentum: Moderate Volume: -52.5% vs avg Volatility: 1.91% Support: $27.06 | Resistance: $30.18 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
Jblack500
Jblack500 May. 5 at 7:32 PM
@MaverikIT @No_Face_character @cynicaloptimist @IsabellaDC @BustaCapital @WAJeff Michelle Ross, stud biotech investor on CNBC right now giving the pump to $RVMD and $ROIV and she is still in $ABVX. i was in roivant for nice gain in the past. She is one of the best to get ideas from
2 · Reply
StockSqueeze_
StockSqueeze_ Apr. 28 at 10:00 PM
Live Account Update Red day today. Down 0.79%. I have two option calls I chased which are both red. Still holding $VOO and $GOOG Picked up $ET and $ROIV today. Back at it again tomorrow. How did you do today? 🤔
0 · Reply
dick_dasterdly
dick_dasterdly Apr. 21 at 10:29 PM
$ROIV Bought this @ $11.13 back on July 18th , 2024. Slowly but surely here folks. Loonnggg play for me. Rich pipeline. And consolidating each and every day..
0 · Reply
NettyLite
NettyLite Apr. 21 at 7:28 PM
$ROIV I thought about also buying Abus but with the slightest bit of research I realized that would be dumb. Abus is roiv's bitch. Y'all didn't do your research now go home and get your shine box
0 · Reply
mj6534
mj6534 Apr. 20 at 10:16 PM
$ABUS $ROIV Androski doing absolutely nothing for us. 🤡
0 · Reply
Thepatientone
Thepatientone Apr. 20 at 7:20 PM
$ABUS - I truly did not understand this rationale. If there was going to be an appeal for the larger amount of the agreement why not proceed to trial... You hold the position that there is an infringement and was willing full for 5 years and you make this decision. I think this new management team came with only one purpose to bring cash to the $ROIV coffins sooner than later. I wonder if we have the right to transparency regarding the logic this management had and not one penny in additional stocks.
3 · Reply
CapitalismUSA
CapitalismUSA Apr. 17 at 11:47 AM
$ABUS $ROIV Agree…voted against the compensation/additional share proposal. Also voted against Androski. We need an independent CEO, not a ROIV puppet
2 · Reply
buffalosoldiertwo
buffalosoldiertwo Apr. 17 at 10:20 AM
$ABUS Why do we need 16MM new shares for executive compensation? It’s obvious they’re winding down the company. Sofia exits before phase 2’s complete, $ROIV takes over the board, company publicly states return litigation process to shareholders signaling no intention of pursuing phase 3 for AB-736, down to 19 employees. We’re obviously in a multi year process of monetizing the assets. This unwinding process is managed by consultants (Morgan Stanley, Goldman Sacks, etc), not anything that $ROIV’s puppet CEO brings to the table. I’m a hard no on item 2. We cannot enrich a C Suite that is adding no value to shareholders. The value was added when the decision was made to monetize all the assets. Done, gone, history. With JP Morgan at your back a monkey could manage the process from here on out. There’s only 19 total employees ($4 MILLION PER EMPLOYEE). For gods sake. No, no, no.
4 · Reply
dick_dasterdly
dick_dasterdly Apr. 17 at 8:57 AM
$ROIV I trust the pipeline. Period.
0 · Reply
sheepmanct
sheepmanct Apr. 15 at 12:27 PM
$ROIV ABUS news if interested- https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-receives-us-fda-fast-track-designation-imdusiran
0 · Reply
Nile1
Nile1 Apr. 14 at 6:37 PM
$ABUS $ABUS so white fort is only halfway from taking over $ROIV , nice 😀
1 · Reply
BreakoutsHappen
BreakoutsHappen Apr. 14 at 10:03 AM
Vix under 19, 50% stocks above ma40. Seems a good day for breakouts. $TIGO $KNSA $ROIV
0 · Reply
Dr_Stoxx
Dr_Stoxx Apr. 13 at 9:38 PM
$ROIV: a hot biotech found with a @MarketSurge scanner. Power gap on Phase III trial data...and only up more from there. 30+ and it'll soar. We're long from the recent dip in the Live Trading Room. #IBDPartner @MarketSurge @InvestorsBusinessDaily
1 · Reply
JFDI
JFDI Apr. 13 at 2:04 PM
$ROIV wow
0 · Reply
Dr_Stoxx
Dr_Stoxx Apr. 9 at 7:34 PM
$ROIV rallied 20% on an update on their pipeline, with progress better than expected. The power gap is holding and now the stock is printing a rounded bottom bonce off the pullback to the rising 50sma. #IBDPartner @MarketSurge @InvestorsBusinessDaily
1 · Reply
bbbloo
bbbloo Apr. 9 at 12:55 PM
$ROIV anybody know why this looks like it is popping a little? ty!
0 · Reply